Apogee jumps as eczema drug delivers lasting benefit in mid-stage trial

Shares of biotech firm Apogee Therapeutics APGE.O rise 22% to $81 premarket

Co says its experimental eczema drug, zumilokibart, showed durable benefit in people with moderate-to-severe atopic dermatitis, a chronic skin condition causing an itchy rash

Adds 75% of patients given the drug every three months and 85% every six months maintained an at least 75% improvement in disease severity at 52 weeks in a mid-stage trial

86% of patients dosed every three months and 78% dosed every six months maintained clear or almost clear skin at 52 weeks - APGE

Co says drug was largely well tolerated, with mild side effects such as eye inflammation and upper respiratory infections

Plans to start late-stage trials in the second-half of 2026

Shares down ~13% YTD vs. ~67% rise in 2025